Source comparison
CJC-1295 vs Modified GRF 1-29 vs Ipamorelin: Mechanism Comparison
CJC-1295 with DAC GHRH receptor agonist with albumin binding 6–8 days Weekly Amplifies natural pulses 2–10× for 7 days 1.5–3× baseline sustained Best for protocols requiring stable elevation with minimal injection frequency. Preserves circadian rhythm Modified
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC
- GHRH receptor agonist with albumin binding
- 6–8 days
- Weekly
- Amplifies natural pulses 2–10× for 7 days
- 1.5–3× baseline sustained
- Best for protocols requiring stable elevation with minimal injection frequency. Preserves circadian rhythm
- Modified GRF 1-29 (CJC-1295 no DAC)
- GHRH receptor agonist without albumin binding
- 30 minutes
- 2–3× daily
- Acute pulse 3–5× baseline per dose
- 1.3–2× baseline (transient)
- Requires structured dosing around fasted/training windows. Allows precise timing control
- Ipamorelin
- Ghrelin receptor agonist (secretagogue)
- 2 hours
- Independent pulse 2–4× baseline
- 1.2–1.8× baseline (transient)
- Mechanistically distinct (bypasses GHRH). Useful for protocols where GHRH pathway is compromised
- Sermorelin
- Unmodified GHRH 1-29 analog
- 10–20 minutes
- 3–4× daily
- Acute pulse 2–3× baseline per dose
- 1.1–1.5× baseline (transient)
- Shortest half-life limits practical use. Primarily historical reference compound